US5407925A - Regional chemotherapy within the central nervous system with 4-hydroperoxycyclophosphamide - Google Patents
Regional chemotherapy within the central nervous system with 4-hydroperoxycyclophosphamide Download PDFInfo
- Publication number
- US5407925A US5407925A US07/788,609 US78860991A US5407925A US 5407925 A US5407925 A US 5407925A US 78860991 A US78860991 A US 78860991A US 5407925 A US5407925 A US 5407925A
- Authority
- US
- United States
- Prior art keywords
- tumor
- hydroperoxycyclophosphamide
- central nervous
- nervous system
- animals
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- WVKOPZMDOFGFAK-UHFFFAOYSA-N 4-hydroperoxycyclophosphamide Chemical compound OOC1=NP(O)(N(CCCl)CCCl)OCC1 WVKOPZMDOFGFAK-UHFFFAOYSA-N 0.000 title claims abstract description 33
- 210000003169 central nervous system Anatomy 0.000 title claims abstract description 11
- 238000002512 chemotherapy Methods 0.000 title description 2
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 44
- 238000000034 method Methods 0.000 claims abstract description 21
- 210000004556 brain Anatomy 0.000 claims description 9
- 210000002330 subarachnoid space Anatomy 0.000 claims description 7
- 208000000172 Medulloblastoma Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 231100000433 cytotoxic Toxicity 0.000 claims description 3
- 230000001472 cytotoxic effect Effects 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 210000000481 breast Anatomy 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000010749 gastric carcinoma Diseases 0.000 claims 1
- 201000005296 lung carcinoma Diseases 0.000 claims 1
- 201000000498 stomach carcinoma Diseases 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 6
- 229940100198 alkylating agent Drugs 0.000 abstract description 2
- 239000002168 alkylating agent Substances 0.000 abstract description 2
- 230000001588 bifunctional effect Effects 0.000 abstract 1
- 230000001461 cytolytic effect Effects 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 17
- 210000004881 tumor cell Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 210000003164 cauda equina Anatomy 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 229960004397 cyclophosphamide Drugs 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000007913 intrathecal administration Methods 0.000 description 3
- 230000011514 reflex Effects 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000009194 climbing Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000000445 cytocidal effect Effects 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- 230000037152 sensory function Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
- 229960001600 xylazine Drugs 0.000 description 2
- RANONBLIHMVXAJ-UHFFFAOYSA-N 4-hydroxycyclophosphamide Chemical compound OC1CCOP(=O)(N(CCCl)CCCl)N1 RANONBLIHMVXAJ-UHFFFAOYSA-N 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000008457 Neurologic Manifestations Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010049680 Quadriparesis Diseases 0.000 description 1
- 206010037714 Quadriplegia Diseases 0.000 description 1
- 101000746366 Rattus norvegicus Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003703 cisterna magna Anatomy 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 231100000409 cytocidal Toxicity 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010231 histologic analysis Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 238000012090 tissue culture technique Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- This invention relates to the use of chemotherapeutic agents. More particularly the invention relates to the use of 4-hydroperoxycyclophosphamide in regional chemotherapy within the central nervous system.
- Cyclophosphamide an alkylating agent with a broad spectrum of anti-tumor activity is actually a prodrug which, to be activated must be converted by hepatic microsomal enzymes into 4-hydrocyclophosphamide. This compound subsequently undergoes spontaneous decomposition to a variety of biologically active compounds. Because of its requirement for hepatic activation, cyclophosphamide cannot be used for regional therapy.
- 4-hydroperoxycyclophosphamide a preactivated derivative of cyclophosphamide, exhibits equal toxicity on a molar basis to cells in vitro as 4-hydrocyclophosphamide, the principal cytotoxic metabolite of cyclophosphamide.
- 4-HC has been shown to be active in vitro against murine leukemia cells (Hilton, Bio. Chem. Pharmacol. Vol. 33, pp. 1867-1872, 1984), human breast cancer cells (Kubota, et al., GANN, Vol. 74, pp.
- Burkitt's lymphoma (De Fabritiis, et al., Blood, Vol. 65, pp. 1064-1070, 1985) cell lines. It is active against human cancer cell line MOLT-4 (a T-cell leukemia) at 2.5 uM, a rhabdomyosarcoma cell line at 8 uM, a breast cancer cell line McF-7 at 9.5 uM and the medulloblastoma cell line TE-671 at 12.8 uM (Arndt et al., Cancer Research, Vol. 47, p. 5932, 1985; Friedman et al., Cancer Research, Vol. 46, p.
- 4-HC is currently used clinically to purge tumor cells from bone marrow prior to autologous marrow transplantation (Korbling, et al., British Journal of Hematology, Vol. 52, pp. 89-96, 1982; and Kizer, et al., Blood, Vol. 65, pp. 1504-1510, 1985).
- a method of treating a tumor in the human body comprises administering an effective amount of 4-hydroperoxycyclophosphamide directly to a tumor within the central nervous system, said tumor being sensitive to the cytotoxic effects of 4-hydroperoxycyclophosphamide.
- the method of the present invention provides the art with a successful means of treating neoplasms for which current therapies are highly unsuccessful.
- the treatment of the present invention results in a delay in the onset of tumor related symptoms as well as in an increase in the survival of tumor-bearing individuals.
- FIG. 1 shows histological analysis of leptomeningeal tumor extension from the cauda equina to the base of the brain.
- FIG. 2 shows the loss of anti-gravity strength and survival time of nude rats injected with TE-671 cells.
- FIG. 3 shows histological sections from animals injected with TE-671 cells. On day eight (panels A and B) small focal nests of tumor cells were observed in the subarachnoid space. By day 20 (panels C and D) confluent filling of the subarachnoid space by tumor cells was observed.
- FIG. 4 shows the effect of intrathecal 4-HC treatment (to a final concentration of 100 uM) on both loss of anti-gravity strength and on survival time.
- FIG. 5 shows the effect of an increased dose of 4-HC (to a final concentration of 250 uM) on both the loss of anti-gravity strength and on survival time.
- Direct regional therapy can be accomplished according to the invention because of the preactivation of the drug. That is, unlike cyclophosphamide, the drug need not be processed by the liver before activity is available to the tumor site.
- the 4-HC is administered directly to the subarachnoid space of the brain.
- a broad spectrum of human tumors can be effectively treated by the method of the present invention. These include but are not limited to medulloblastoma, glioma, carcinoma, rhabdomyosarcoma, breast cancer, sarcoma, melanoma, leukemia, and lymphoma. Medulloblastomas, the most common primary central nervous system malignancy in childhood, is a highly aggressive neoplasm with a marked predilection for leptomeningeal dissemination. Although therapeutic intervention for such dissemination in this tumor is often unsuccessful, the method of the present invention has proved successful in both delaying the onset of associated symptoms as well as increasing the median survival of the individuals affected.
- administration of 4-hydroperoxycyclophosphamide can be by any means which causes a localized, regional effect.
- the drug may be administered intrathecally or intraventricularly, directly into a tumor mass, or directly in the arterial blood supply to a tumor.
- concentrations of 4-hydroxycyclophosphamide of up to 20 uM are achieved.
- Direct regional administration of 4-hydroperoxycyclophosphamide can achieve much higher concentrations.
- Effective doses of 4-hydroperoxycyclophosphamide are generally those which create a regional concentration of between about 150 uM and about 2000 uM. Preferred doses are above about 200 uM; and most preferred are above about 500 uM. Doses between about 1000 uM and about 2000 uM can be employed. As is readily apparent to those of skill in the art, maximum concentrations are desirable for their cytocidal effects on the tumor cells; however these should not cause toxic side effects to other portions of the treated individual.
- Precise doses and regimens can be empirically determined by those of skill in the art depending upon the particular condition of the patient and the tumor involved.
- Generally weekly administration of 4-HC is desirable, with monitoring for toxicity and efficacy. A course of about six weekly injections can be employed.
- To monitor toxicity neurological damage is measured and observed. For example, functional neurological loss, numbness, paralysis, or pain may be observed and should be minimized.
- 4-HC may be administered alone or in combination with other chemotherapeutic agents, such as methotrexate.
- This example describes the animal model which was used to test the efficacy of the method of the present invention in vivo in whole animals.
- mice Female athymic nude rats (200-250 grams), maintained in the Duke University Animal Laboratory and Isolation Facility, were anesthetized with ketamine/xylazine (55 mg/ml ketamine, 9 mg/ml xylazine), administered i.p. at a volume of 1 ml/kg.
- Subarachnoid catheters were placed using a modification of the technique described by Kooistra, et al. (Cancer Research, vol. 46, pp. 317-323, 1986). Briefly, rats were placed with the neck flexed 90 degrees in a stereotactic frame with tilt adaptor (David Kopf Instruments, Tujunga, Calif.).
- a midline sagittal incision was made from the inion to the laminal arch of C1.
- the atlanto-occipital membrane was exposed by sharp dissection.
- the tough, outer membrane and underlying cisterna magna dura were opened using the tip of a 20-guage needle as a knife, under 5-10 ⁇ magnification using an operating microscope (Zeiss OPMI 99).
- a PE-10 catheter (Intramedic, Clay Adams) with a 5-0 stainless steel wire styler was inserted into the subarachnoid space and passed along the posterior aspect of the spinal cord to the lumbar region (8.5 cm).
- a loose knot was tied in the catheter and fixed with dental epoxy (Lang Dental Manufacturing Co., Chicago, Ill.).
- the catheter was passed through the skin lateral to the incision using a 19-gauge needle.
- the wound was closed in three layers using 6-0 Ethicon (Ethicon Co., Somerville, N.J.). After documenting spontaneous flow of CSF, the catheter was concluded using a short length of 2-0 stainless steel wire.
- the animals were allowed to recover for three to five days and only animals showing normal motor and sensory function were used in experiments (greater than 99% of animals undergoing catheter placement).
- Injections of tumor cells or drugs were performed through the catheter in volumes of 20-40 ul using a Hamilton syringe and injector equipped with a 30 gauge needle. All injections were followed by 20 ul of sterile saline to rinse the cathether.
- This example shows the effect of tumor inoculation volume on the nude rats.
- This example shows the effects of tumor inoculation on the nude rats.
- Rats were inoculated with tumor cells as described above in example 1. Animals were followed until death with daily weights and neurologic examinations, including the presence or absence of the stepping and placing reflex, and the ability to negotiate a 60 degree incline ramp. These functions have been reported to correlate with subarachnoid tumor growth in other systems, in contrast to sensory function tests (Kooistra et al., Cancer Research, Vol.. 96, pp. 317-323, 1986).
- This example demonstrates the effects of regional administration of 4-HC on the loss of the antigravity response and on the survival rate caused by the tumor xenografts.
- 4-HC was diluted in PBS and administered via subarachnoid catheter within one hour of its preparation on day 8 following tumor inoculation.
- one group of 27 animals was treated with 40 ul 1 mM 4-HC to provide a final CSF concentration of 100 uM, based on the rat CSF volume of 400 ul (Meek and Neff, Neuropharmacology, Vol. 12, pp. 497-499, 1973).
- a control group of 10 animals received 40 ul PBS. Animals were followed as described above, with histopathology obtained on all animals after death. Statistical analysis was performed using the Wilcoxan rank sum test. A P of less than 0.05 was considered significant.
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A method of treating human tumors is provided in which tumors are regionally treated with a cytolytic, pre-activated, bifunctional alkylating agent, namely 4-hydroperoxycyclophosphamide. The treatment is effective against a variety of tumor types within the central nervous systems.
Description
The U.S. government has a paid up license in this invention and the right in limited circumstances to require the patent owner to license others on reasonable terms as provided for by the terms of grants numbered CA11898, CA43722, CA44640, NS20023. NS00958, and T32-NS07304, awarded by the National Institutes of Health.
This application is a continuation of application Ser. No. 328,921, filed Mar. 27, 1989, now abandoned.
This invention relates to the use of chemotherapeutic agents. More particularly the invention relates to the use of 4-hydroperoxycyclophosphamide in regional chemotherapy within the central nervous system.
Cyclophosphamide, an alkylating agent with a broad spectrum of anti-tumor activity is actually a prodrug which, to be activated must be converted by hepatic microsomal enzymes into 4-hydrocyclophosphamide. This compound subsequently undergoes spontaneous decomposition to a variety of biologically active compounds. Because of its requirement for hepatic activation, cyclophosphamide cannot be used for regional therapy.
In contrast, 4-hydroperoxycyclophosphamide (4-HC), a preactivated derivative of cyclophosphamide, exhibits equal toxicity on a molar basis to cells in vitro as 4-hydrocyclophosphamide, the principal cytotoxic metabolite of cyclophosphamide. (Redwood, et al., preceding of the American Association of Cancer Research, Vol. 23, p. 169, 1982.) 4-HC has been shown to be active in vitro against murine leukemia cells (Hilton, Bio. Chem. Pharmacol. Vol. 33, pp. 1867-1872, 1984), human breast cancer cells (Kubota, et al., GANN, Vol. 74, pp. 437-444, 1983). and Burkitt's lymphoma (De Fabritiis, et al., Blood, Vol. 65, pp. 1064-1070, 1985) cell lines. It is active against human cancer cell line MOLT-4 (a T-cell leukemia) at 2.5 uM, a rhabdomyosarcoma cell line at 8 uM, a breast cancer cell line McF-7 at 9.5 uM and the medulloblastoma cell line TE-671 at 12.8 uM (Arndt et al., Cancer Research, Vol. 47, p. 5932, 1985; Friedman et al., Cancer Research, Vol. 46, p. 2827, 1986.) 4-HC is currently used clinically to purge tumor cells from bone marrow prior to autologous marrow transplantation (Korbling, et al., British Journal of Hematology, Vol. 52, pp. 89-96, 1982; and Kizer, et al., Blood, Vol. 65, pp. 1504-1510, 1985).
In addition, it has been shown that direct intrathecal administration of 4-HC can achieve drug concentrations of 100 uM in the cerebrospinal fluid (which would be cytocidal in vitro) without producing toxicity. (Arndt et al., Cancer Research, Vol. 47, pp. 5932-5934, 1987).
Despite these preliminary findings, it has yet to be established whether 4-HC can effectively treat tumors in vivo. There is a distinct need in the art of tumor therapy for agents which can affect the growth of compartmentalized tumors. Such tumors are often aggressive and difficult to treat even after surgery and irradiation.
It is an object of the invention to provide a method of treating tumors which can grow and metastasize within the central nervous system.
In accordance with this invention, a method of treating a tumor in the human body is provided which comprises administering an effective amount of 4-hydroperoxycyclophosphamide directly to a tumor within the central nervous system, said tumor being sensitive to the cytotoxic effects of 4-hydroperoxycyclophosphamide.
The method of the present invention provides the art with a successful means of treating neoplasms for which current therapies are highly unsuccessful. The treatment of the present invention results in a delay in the onset of tumor related symptoms as well as in an increase in the survival of tumor-bearing individuals.
FIG. 1 shows histological analysis of leptomeningeal tumor extension from the cauda equina to the base of the brain.
FIG. 2 shows the loss of anti-gravity strength and survival time of nude rats injected with TE-671 cells.
FIG. 3 shows histological sections from animals injected with TE-671 cells. On day eight (panels A and B) small focal nests of tumor cells were observed in the subarachnoid space. By day 20 (panels C and D) confluent filling of the subarachnoid space by tumor cells was observed.
FIG. 4 shows the effect of intrathecal 4-HC treatment (to a final concentration of 100 uM) on both loss of anti-gravity strength and on survival time.
FIG. 5 shows the effect of an increased dose of 4-HC (to a final concentration of 250 uM) on both the loss of anti-gravity strength and on survival time.
It is a finding of the present invention that direct administration of 4-hydroperoxycyclophosphamide to the central nervous system containing a tumor can have a positive effect on both the survival time and the onset of tumor-related symptoms. A very broad spectrum of human tumors can be treated by the method of the present invention. Particularly preferred tumors for treatment in the present mode are those that commonly metastasize to the brain. These include carcinomas of the lung, breast, stomach, as well as melanomas. Tumors which invade the central nervous system can be treated by the method of the present invention.
Direct regional therapy can be accomplished according to the invention because of the preactivation of the drug. That is, unlike cyclophosphamide, the drug need not be processed by the liver before activity is available to the tumor site. In one preferred embodiment, the 4-HC is administered directly to the subarachnoid space of the brain.
A broad spectrum of human tumors can be effectively treated by the method of the present invention. These include but are not limited to medulloblastoma, glioma, carcinoma, rhabdomyosarcoma, breast cancer, sarcoma, melanoma, leukemia, and lymphoma. Medulloblastomas, the most common primary central nervous system malignancy in childhood, is a highly aggressive neoplasm with a marked predilection for leptomeningeal dissemination. Although therapeutic intervention for such dissemination in this tumor is often unsuccessful, the method of the present invention has proved successful in both delaying the onset of associated symptoms as well as increasing the median survival of the individuals affected.
In accordance with the present invention, administration of 4-hydroperoxycyclophosphamide can be by any means which causes a localized, regional effect. For example, the drug may be administered intrathecally or intraventricularly, directly into a tumor mass, or directly in the arterial blood supply to a tumor. These and other techniques, which are termed herein "direct administration to a region of the body," are well known in the medical arts.
After systemic administration of cyclophosphamide, concentrations of 4-hydroxycyclophosphamide of up to 20 uM are achieved. Direct regional administration of 4-hydroperoxycyclophosphamide can achieve much higher concentrations. Effective doses of 4-hydroperoxycyclophosphamide are generally those which create a regional concentration of between about 150 uM and about 2000 uM. Preferred doses are above about 200 uM; and most preferred are above about 500 uM. Doses between about 1000 uM and about 2000 uM can be employed. As is readily apparent to those of skill in the art, maximum concentrations are desirable for their cytocidal effects on the tumor cells; however these should not cause toxic side effects to other portions of the treated individual.
Precise doses and regimens can be empirically determined by those of skill in the art depending upon the particular condition of the patient and the tumor involved. Generally weekly administration of 4-HC is desirable, with monitoring for toxicity and efficacy. A course of about six weekly injections can be employed. To monitor toxicity neurological damage is measured and observed. For example, functional neurological loss, numbness, paralysis, or pain may be observed and should be minimized. 4-HC may be administered alone or in combination with other chemotherapeutic agents, such as methotrexate.
The following examples are not intended to limit the scope of the invention which has been described above.
This example describes the animal model which was used to test the efficacy of the method of the present invention in vivo in whole animals.
Female athymic nude rats (200-250 grams), maintained in the Duke University Animal Laboratory and Isolation Facility, were anesthetized with ketamine/xylazine (55 mg/ml ketamine, 9 mg/ml xylazine), administered i.p. at a volume of 1 ml/kg. Subarachnoid catheters were placed using a modification of the technique described by Kooistra, et al. (Cancer Research, vol. 46, pp. 317-323, 1986). Briefly, rats were placed with the neck flexed 90 degrees in a stereotactic frame with tilt adaptor (David Kopf Instruments, Tujunga, Calif.). A midline sagittal incision was made from the inion to the laminal arch of C1. The atlanto-occipital membrane was exposed by sharp dissection. The tough, outer membrane and underlying cisterna magna dura were opened using the tip of a 20-guage needle as a knife, under 5-10× magnification using an operating microscope (Zeiss OPMI 99). A PE-10 catheter (Intramedic, Clay Adams) with a 5-0 stainless steel wire styler was inserted into the subarachnoid space and passed along the posterior aspect of the spinal cord to the lumbar region (8.5 cm). A loose knot was tied in the catheter and fixed with dental epoxy (Lang Dental Manufacturing Co., Chicago, Ill.). The catheter was passed through the skin lateral to the incision using a 19-gauge needle. The wound was closed in three layers using 6-0 Ethicon (Ethicon Co., Somerville, N.J.). After documenting spontaneous flow of CSF, the catheter was concluded using a short length of 2-0 stainless steel wire. The animals were allowed to recover for three to five days and only animals showing normal motor and sensory function were used in experiments (greater than 99% of animals undergoing catheter placement). Injections of tumor cells or drugs were performed through the catheter in volumes of 20-40 ul using a Hamilton syringe and injector equipped with a 30 gauge needle. All injections were followed by 20 ul of sterile saline to rinse the cathether.
The establishment, characterization and tissue culture techniques for the human medulloblastoma cell line TE-671 have been previously described (McCallister et al., Int. J. Cancer, Vol. 20, pp. 206-212, 1977; and Friedman et al., J. Neurapathol. Exp. Neurol., Vol. 42, pp. 485-513, 1983). Cells were harvested in log phase into phosphate buffered saline (PBS) at 6.2×106 or 1.25×107 viable cells/ml, (as assessed by trypan blue exclusion) and 5×105 cells injected into subarachnoid catheters within 1 hour of harvest. Preliminary studies were performed to determine the optimum volume of tumor injection. Groups of 5 animals each were injected with 5×105 cells in either 20 ul or 40 ul.
This example shows the effect of tumor inoculation volume on the nude rats.
The effect of altering the volume of inoculated tumor cells was assessed using a constant dose of 5×105 TE-671 cells. At a 20 ul inoculation volume, animals developed progressive neurologic deficits and died at day 14-18. With a 40 ul injection volume, animals died by day 21-27, with leptomeningeal tumor extending from the cauda equina to the base of the brain (FIG. 1). For all further studies a 40 ul injection volume was used.
Histologic analysis documented leptomeningeal tumor extension from the cauda equina to the low cervical cord. The entire spine and skull were removed en bloc and fixed in 10% formalin for 7-10 days, then decalcified using RDO solution (Apex Engineering Products Co., Plainfield, Ill.). The brain and spinal cord were cut into six sections. Coronal sections of the brain were taken at the level of the coronal suture and the pituitary gland. Axial sections of the spinal cord were taken from the cervical, thoracic, and lumbar cord, and the cauda equina. Sections were embedded in paraffin, and 6 um sections were stained with hematoxylin and eosin and examined by light microscopy.
This example shows the effects of tumor inoculation on the nude rats.
Rats were inoculated with tumor cells as described above in example 1. Animals were followed until death with daily weights and neurologic examinations, including the presence or absence of the stepping and placing reflex, and the ability to negotiate a 60 degree incline ramp. These functions have been reported to correlate with subarachnoid tumor growth in other systems, in contrast to sensory function tests (Kooistra et al., Cancer Research, Vol.. 96, pp. 317-323, 1986).
Animals injected with 5×105 TE-671 cells in 40 ul developed a progressive quadriparesis, with loss of ramp climbing ability and stepping and placing reflexes by day 18-24, with death generally occurring by day 21-27 (FIG. 2).
On day 4, no tumor could be demonstrated. By day 8, sections from most animals showed focal small nests of tumor cells in the subarachnoid space (FIGS. 3A, B). By day 20, sections from most animals showed confluent filling of the subarachnoid space by tumor cells, which extended from the base of the brain to the cauda equina (FIG. 3C, D).
This example demonstrates the effects of regional administration of 4-HC on the loss of the antigravity response and on the survival rate caused by the tumor xenografts.
4-HC, was diluted in PBS and administered via subarachnoid catheter within one hour of its preparation on day 8 following tumor inoculation. In the first experiment, one group of 27 animals was treated with 40 ul 1 mM 4-HC to provide a final CSF concentration of 100 uM, based on the rat CSF volume of 400 ul (Meek and Neff, Neuropharmacology, Vol. 12, pp. 497-499, 1973). A control group of 10 animals received 40 ul PBS. Animals were followed as described above, with histopathology obtained on all animals after death. Statistical analysis was performed using the Wilcoxan rank sum test. A P of less than 0.05 was considered significant.
Treatment with intrathecal 4-HC (final concentration 100 uM) resulted in a delay in the loss of antigravity strength (p=0.036) and an increase in median survival of 20% (p=0.04) (FIG. 4). Increase in the dose of 4-HC (to a final concentration of 250 uM) resulted in a further delay in the loss of antigravity strength (p less than 0.01) and an increase in median survival of 36% (p less than 0.01) (FIG. 5). There was no clinical evidence of toxicity with either dose. In both treatment studies, loss of stepping and placing reflexes and ramp climbing ability preceded death by approximately 3 days. Sections from all animals in both the 4-HC-treated and saline-treated control groups showed a diffuse subarachnoid infiltrate of tumor cells extending from the base of the brain to the cauda equina.
Claims (10)
1. A method of treating a tumor in the human body, comprising:
administering an effective amount of 4-hydroperoxycyclophosphamide directly to a tumor within the central nervous system, said tumor being sensitive to the cytotoxic affects of 4-hydroperoxycyclophosphamide.
2. The method of claim 1 wherein the tumor has metastasized to the brain.
3. The method of claim 2 wherein the tumor is a medulloblastoma.
4. The method of claim 2 wherein the tumor is a carcinoma selected from the group consisting of lung, breast and stomach carcinomas or is a melanoma.
5. The method of claim 1 wherein the 4-hydroperoxycyclophosphamide is administered intrathecally.
6. The method of claim 1 wherein the 4-hydroperoxycyclophosphamide is administered to the subarachnoid space.
7. The method of claim 1 wherein the 4-hydroperoxycyclophosphamide is administered intraventricularly.
8. The method of claim 1 wherein the effective amount of 4-hydroperoxycyclophosphamide creates a concentration within the central nervous system of between about 150 and about 2000 μM.
9. The method of claim 8 wherein the effective amount of 4-hydroperoxycyclophosphamide creates a concentration within the central nervous system of between about 1000 μM and about 2000 μM.
10. The method of claim 8 wherein the regional concentration is between about 500 uM and 1000 uM.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/788,609 US5407925A (en) | 1989-03-27 | 1991-11-06 | Regional chemotherapy within the central nervous system with 4-hydroperoxycyclophosphamide |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32892189A | 1989-03-27 | 1989-03-27 | |
| US07/788,609 US5407925A (en) | 1989-03-27 | 1991-11-06 | Regional chemotherapy within the central nervous system with 4-hydroperoxycyclophosphamide |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US32892189A Continuation | 1989-03-27 | 1989-03-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US5407925A true US5407925A (en) | 1995-04-18 |
Family
ID=23283049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US07/788,609 Expired - Lifetime US5407925A (en) | 1989-03-27 | 1991-11-06 | Regional chemotherapy within the central nervous system with 4-hydroperoxycyclophosphamide |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US5407925A (en) |
| EP (2) | EP0465512B1 (en) |
| JP (1) | JPH04505757A (en) |
| AT (1) | ATE102832T1 (en) |
| AU (1) | AU642868B2 (en) |
| CA (1) | CA2049341C (en) |
| DE (1) | DE69007472T2 (en) |
| DK (1) | DK0465512T3 (en) |
| ES (1) | ES2062517T3 (en) |
| WO (1) | WO1990011078A2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040147582A1 (en) * | 1999-07-23 | 2004-07-29 | University Of California Regents | Use of etodolac for the treatment of chronic lymphocytic leukemia |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6251886B1 (en) | 1998-12-07 | 2001-06-26 | Schering Corporation | Methods of using temozolomide in the treatment of cancers |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3808297A (en) * | 1971-06-28 | 1974-04-30 | Shionogi & Co | Hydroperoxy substituted cyclic phosphamides |
-
1990
- 1990-03-16 AT AT90905145T patent/ATE102832T1/en not_active IP Right Cessation
- 1990-03-16 ES ES90905145T patent/ES2062517T3/en not_active Expired - Lifetime
- 1990-03-16 CA CA002049341A patent/CA2049341C/en not_active Expired - Lifetime
- 1990-03-16 WO PCT/US1990/001298 patent/WO1990011078A2/en not_active Ceased
- 1990-03-16 DE DE69007472T patent/DE69007472T2/en not_active Expired - Fee Related
- 1990-03-16 AU AU53374/90A patent/AU642868B2/en not_active Ceased
- 1990-03-16 JP JP2505078A patent/JPH04505757A/en active Pending
- 1990-03-16 DK DK90905145.0T patent/DK0465512T3/en active
- 1990-03-16 EP EP90905145A patent/EP0465512B1/en not_active Expired - Lifetime
- 1990-03-16 EP EP19930106295 patent/EP0567031A1/en not_active Withdrawn
-
1991
- 1991-11-06 US US07/788,609 patent/US5407925A/en not_active Expired - Lifetime
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3808297A (en) * | 1971-06-28 | 1974-04-30 | Shionogi & Co | Hydroperoxy substituted cyclic phosphamides |
Non-Patent Citations (40)
| Title |
|---|
| Alberts et al., "Tabular Summary of Pharmocokinetic Parameters Relevant to In Vitro Drug Assay," ed. by Salmon, Cloning of Human Tumor Stem Cells, pp. 351-359. |
| Alberts et al., Tabular Summary of Pharmocokinetic Parameters Relevant to In Vitro Drug Assay, ed. by Salmon, Cloning of Human Tumor Stem Cells, pp. 351 359. * |
| Arndt et al., "Cerebrospinal Fluid Penetration of Active Metabolites of Cyclophosphamide and Ifosfamide in Rhesus Monkeys," Can. Res. (1988), 48:2113-2115. |
| Arndt et al., "Intrathecal Admimistration of 4-Hydroperoxycyclophosphamide in Rhesus Monkeys", Cancer Research (1987) vol. 47 pp. 5932-5934. |
| Arndt et al., Cerebrospinal Fluid Penetration of Active Metabolites of Cyclophosphamide and Ifosfamide in Rhesus Monkeys, Can. Res. (1988), 48:2113 2115. * |
| Arndt et al., Intrathecal Admimistration of 4 Hydroperoxycyclophosphamide in Rhesus Monkeys , Cancer Research (1987) vol. 47 pp. 5932 5934. * |
| Boerrigter et al., "Intradermal Administration of 4-Hydroperoxycyclophosphamide during Contact Sensitization Potentiates Effector T-Cell Responsiveness in Draining Lymph Nodes," Immunopharmacology (1986), 11:13-20. |
| Boerrigter et al., "Local Administration of the Cytostatic Drug 4-Hydroperoxycyclophosphamide(4-HPCY) Facilities Cell-Mediated Immune reactions", (1984) Clin. Exp. Immunol., 58:161-166. |
| Boerrigter et al., "Potentiation of T-Cell Mediated Immunity by Local Chemotherapy," Agents and Actions, (1984), 15:77-79. |
| Boerrigter et al., Intradermal Administration of 4 Hydroperoxycyclophosphamide during Contact Sensitization Potentiates Effector T Cell Responsiveness in Draining Lymph Nodes, Immunopharmacology (1986), 11:13 20. * |
| Boerrigter et al., Local Administration of the Cytostatic Drug 4 Hydroperoxycyclophosphamide(4 HPCY) Facilities Cell Mediated Immune reactions , (1984) Clin. Exp. Immunol., 58:161 166. * |
| Boerrigter et al., Potentiation of T Cell Mediated Immunity by Local Chemotherapy, Agents and Actions, (1984), 15:77 79. * |
| Carter et al., "The integration of Chemotherapy into a Combiend Modality Approach for Cancer Treatment," Cancer Treatment Review (1975), 2:193-214. |
| Carter et al., The integration of Chemotherapy into a Combiend Modality Approach for Cancer Treatment, Cancer Treatment Review (1975), 2:193 214. * |
| Chang, "Differential Sensitivity of Pancreatic Adenocarcinoma Cell Lines to Chemotherapeutic Agents in Culture," Cancer Treat. Rep., (1983), 67:355-359. |
| Chang, Differential Sensitivity of Pancreatic Adenocarcinoma Cell Lines to Chemotherapeutic Agents in Culture, Cancer Treat. Rep., (1983), 67:355 359. * |
| Colvin et al., "Pharmacology of Cyclophosphamide and Metabolites," Cancer Treatment Reports (1981), 65(Supp. 3):89-95. |
| Colvin et al., Pharmacology of Cyclophosphamide and Metabolites, Cancer Treatment Reports (1981), 65(Supp. 3):89 95. * |
| DeFabritiis et al., "Elimination of Clonogenic Burkitt's Lymphoma Cells from Human Bone Marrow Using 4-Hydroperoxycyclophosphamide in Combination with Monoclonal Antibodies and Complement," Blood (1985), 65:1064-1070. |
| DeFabritiis et al., Elimination of Clonogenic Burkitt s Lymphoma Cells from Human Bone Marrow Using 4 Hydroperoxycyclophosphamide in Combination with Monoclonal Antibodies and Complement, Blood (1985), 65:1064 1070. * |
| Frei, III et al., "Dose: A Critical Factor in Cancer Chemotherapy," Amer. J. Med. (1980), 69:585-594. |
| Frei, III et al., Dose: A Critical Factor in Cancer Chemotherapy, Amer. J. Med. (1980), 69:585 594. * |
| Friedman et al., "Experimental Chemotherapy of Human Medulloblastoma Cell Lines and Transplantable Xenografts with Bifunctional Alkylating Agents," Can. Res. (1988), 48:4189-4195. |
| Friedman et al., Experimental Chemotherapy of Human Medulloblastoma Cell Lines and Transplantable Xenografts with Bifunctional Alkylating Agents, Can. Res. (1988), 48:4189 4195. * |
| Fuchs et al., "Activity of Intrathecal 4-HC in a Nude Rat Model of Human Neoplastic Meningitis," Cancer Research (1990),50:1954-1959. |
| Fuchs et al., Activity of Intrathecal 4 HC in a Nude Rat Model of Human Neoplastic Meningitis, Cancer Research (1990),50:1954 1959. * |
| Kubota et al., "Antitumor Effect and Metabolic Activation of Cyclophosphamide and 4-HC in the Human Breast Carcinoma (MX-1)-Nude Mouse System," Gann (1983),74:437-444. |
| Kubota et al., Antitumor Effect and Metabolic Activation of Cyclophosphamide and 4 HC in the Human Breast Carcinoma (MX 1) Nude Mouse System, Gann (1983),74:437 444. * |
| Mirabelli et al., "A Murine Model to Evaluate the Ability of In Vitro Clonogenic Assays to Predict the Response to Tumors in Vivo," Cancer Res. (1988), 48:5447-5454. |
| Mirabelli et al., A Murine Model to Evaluate the Ability of In Vitro Clonogenic Assays to Predict the Response to Tumors in Vivo, Cancer Res. (1988), 48:5447 5454. * |
| Niell et al., "The Use of a Tumor Colony Assay in Predicting Chemotherapeutic Drug Response in Murine Bladder Cancer," Cancer (1983), 52:619-625. |
| Niell et al., The Use of a Tumor Colony Assay in Predicting Chemotherapeutic Drug Response in Murine Bladder Cancer, Cancer (1983), 52:619 625. * |
| O Connell, Current Status of Chemotherapy for Advanced Pancreatic and Gastric Cancer, J. Clin. Oncology (1985), 3:1032 1039. * |
| O'Connell, "Current Status of Chemotherapy for Advanced Pancreatic and Gastric Cancer," J. Clin. Oncology (1985), 3:1032-1039. |
| Schein, "The Role of Chemotherapy in the Management of Gastric and Pancreatic Carcinomas," Seminars in Oncology (1985), 12:49-60. |
| Schein, The Role of Chemotherapy in the Management of Gastric and Pancreatic Carcinomas, Seminars in Oncology (1985), 12:49 60. * |
| Scheper et al., "Immunotherapeutic Effects of Local Chemotherapy with an Active Metobolite of Cyclophosphamide," Meth. and Find Exptl. Clin Pharmacol. (1987), 9:611-615. |
| Scheper et al., Immunotherapeutic Effects of Local Chemotherapy with an Active Metobolite of Cyclophosphamide, Meth. and Find Exptl. Clin Pharmacol. (1987), 9:611 615. * |
| Selby et al., "A Critical Appraisal of the Human Tumor Stem-Cell Assay," New Eng. J. Med., (1983),308:129-134. |
| Selby et al., A Critical Appraisal of the Human Tumor Stem Cell Assay, New Eng. J. Med., (1983),308:129 134. * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040147582A1 (en) * | 1999-07-23 | 2004-07-29 | University Of California Regents | Use of etodolac for the treatment of chronic lymphocytic leukemia |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0465512A1 (en) | 1992-01-15 |
| DE69007472T2 (en) | 1994-07-14 |
| WO1990011078A2 (en) | 1990-10-04 |
| EP0567031A1 (en) | 1993-10-27 |
| DK0465512T3 (en) | 1994-05-30 |
| JPH04505757A (en) | 1992-10-08 |
| EP0465512B1 (en) | 1994-03-16 |
| CA2049341A1 (en) | 1990-09-28 |
| AU5337490A (en) | 1990-10-22 |
| ES2062517T3 (en) | 1994-12-16 |
| ATE102832T1 (en) | 1994-04-15 |
| DE69007472D1 (en) | 1994-04-21 |
| CA2049341C (en) | 2001-02-20 |
| AU642868B2 (en) | 1993-11-04 |
| WO1990011078A8 (en) | 2005-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Harbaugh et al. | Preliminary report: intracranial cholinergic drug infusion in patients with Alzheimer's disease | |
| Degen et al. | Safety and efficacy of convection-enhanced delivery of gemcitabine or carboplatin in a malignant glioma model in rats | |
| Levy et al. | Treatment of chronic pain by deep brain stimulation: long term follow-up and review of the literature | |
| Jurna et al. | Intrathecal injection of acetylsalicylic acid, salicylic acid and indometacin depresses C fibre-evoked activity in the rat thalamus and spinal cord | |
| EP1066830B1 (en) | Uses and compositions for treating primary and secondary tumors of the central nervous system (cns) | |
| Cotton et al. | Anticonvulsant effects of magnesium sulfate on hippocampal seizures: therapeutic implications in preeclampsia-eclampsia | |
| Hasser et al. | Reflex effect of vasopressin after blockade of V1 receptors in the area postrema. | |
| Fuchs et al. | Activity of intrathecal 4-hydroperoxycyclophosphamide in a nude rat model of human neoplastic meningitis | |
| Friedman et al. | Chemotherapy of subcutaneous and intracranial human medulloblastoma xenografts in athymic nude mice | |
| Kooistra et al. | Development of experimental models for meningeal neoplasia using intrathecal injection of 9L gliosarcoma and Walker 256 carcinosarcoma in the rat | |
| Yu et al. | Response of murine tumors to matrix-associated cisplatin intratumoral implants | |
| Emerich et al. | Bradykinin modulation of tumor vasculature: I. Activation of B2 receptors increases delivery of chemotherapeutic agents into solid peripheral tumors, enhancing their efficacy | |
| Bufalari et al. | Preemptive carprofen for peri-operative analgesia in dogs undergoing Tibial Plateau Leveling Osteotomy (TPLO): a prospective, randomized, blinded, placebo controlled clinical trial | |
| US5407925A (en) | Regional chemotherapy within the central nervous system with 4-hydroperoxycyclophosphamide | |
| Norrell et al. | Brain Tumor Chemotherapy With Methotrexate Given Intrathecally: A New Technique | |
| US20100035952A1 (en) | Radiosensitizer Formulations and Methods for Use | |
| Schuster et al. | Intraarterial therapy of human glioma xenografts in athymic rats using 4-hydroperoxycyclophosphamide | |
| Krushelnycky et al. | Development of a large-animal human brain tumor xenograft model in immunosuppressed cats | |
| CA1330422C (en) | Reduction of neurotoxic effects of cytotoxic agents | |
| Archer et al. | Intrathecal busulfan treatment of human neoplastic meningitis in athymic nude rats | |
| Sutton et al. | Reduction of vinblastine neurotoxicity in mice utilizing a collagen matrix carrier | |
| Bergman et al. | A rat model of leptomeningeal human neoplastic xenografts | |
| YATES et al. | Experimental studies in regional perfusion | |
| Wu et al. | Section on tumors: Young Investigator Award: local release of carboplatin via an Alzet mini-osmotic pump prolongs survival in a rat brainstem tumor model | |
| HORI et al. | Experimental therapy of human oligodendroglioma transplanted into nude mice and its clinical trial in the donor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
| FPAY | Fee payment |
Year of fee payment: 4 |
|
| FPAY | Fee payment |
Year of fee payment: 8 |
|
| FPAY | Fee payment |
Year of fee payment: 12 |